EUVIMEDEUVIMED entdecken
Crossref

Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren’s disease

Baptiste Chevet, Valérie Devauchelle-Pensec, Elena Pontarini, Valentin Baloche, Michele Bombardieri, Simon J Bowman, Michael Barnes, Antoine G Sreih, Jinqi Liu, Sheila Kelly, Antonia Christodoulou, Philippe Moingeon und 13 weitere

Annals of the Rheumatic Diseases · 2026

DOI: 10.1016/j.ard.2025.11.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026. Verfasst von Baptiste Chevet und 24 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department, CHU Brest, Brest, France; LBAI, UMR1227, INSERM, University of Brest, Brest, France. Hauptthemen laut MEDLINE: Abatacept, Antirheumatic Agents, Hydroxychloroquine, Leflunomide. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Horizon 2020 Framework Programme, European Federation of Pharmaceutical Industries and Associations, Innovative Medicines Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Sjögren's disease (SjD) is clinically and biologically heterogeneous, and no immunomodulatory drug has yet demonstrated efficacy in phase 3 trials. We previously identified 4 transcriptomic endotypes in SjD patients using whole-blood RNA sequencing. We hypothesised that these endotypes may predict differential therapeutic responses. METHODS: We analysed clinical, biological, and transcriptomic data from 3 randomised controlled trials evaluating hydroxychloroquine-leflunomide (HCQ-LEF; n = 18; RepurpSS-I trial), rituximab (RTX; n = 56; TRACTISS trial), and abatacept (n = 117). Patients were assigned to the 4 endotypes using semisupervised uniform manifold approximation and projection combined with a support vector machine model. Demographics, disease activity, and therapeutic response, as defined by the Sjögren Tool for Assessing Response index, were compared across clusters in both pooled and individual trial analyses. RESULTS: Of 170 patients, 81, 24, 80, and 6 were classified into clusters 1 to 4, respectively. European Alliance of Associations for Rheumatology (EULAR) Sjögren's Syndrome Patient Reported Index scores were comparable across clusters, while the EULAR Sjögren's Syndrome Disease Activity Index was significantly higher in clusters 3 and 4 vs clusters 1 and 2 (P = .003). In pooled analyses, patients in cluster 1 had significantly greater response rates with active treatment vs placebo (61.5% vs 32.6%: P = .016), with a similar trend in the RTX trial. In contrast, patients in cluster 3 benefitted from HCQ-LEF, whereas cluster 2 (healthy-like patients) showed no significant response to any therapy. CONCLUSIONS: Transcriptomic stratification of SjD patients revealed differential responses to HCQ-LEF and RTX. Notably, healthy-like patients exhibited minimal treatment response, suggesting they may be unsuitable candidates for future therapeutic trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AbataceptAntirheumatic AgentsHydroxychloroquineLeflunomideRituximabSjogren's SyndromeTranscriptomeAdultAgedFemaleHumansMaleMiddle AgedDrug Therapy, CombinationRandomized Controlled Trials as TopicTreatment Outcome

Substanzen

AbataceptAntirheumatic AgentsHydroxychloroquineLeflunomideRituximab

Autor:innen und Institutionen

  • Rheumatology Department, CHU Brest, Brest, France; LBAI, UMR1227, INSERM, University of Brest, Brest, France.
  • Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, London, UK.
  • Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Department of Rheumatology, University Hospitals Birmingham, Birmingham, UK; School of Infection, Inflammation & Immunology, University of Birmingham, Birmingham, UK; National Institute for Health and Care Research (NIH…
  • Centre for Translational Bioinformatics, Queen Mary, University of London (QMUL), London, UK.
  • Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA; Bristol-Myers Squibb, Lawrenceville, NJ, USA; Cullinan Therapeutics, Boston, MA, USA.

Förderung

  • Horizon 2020 Framework Programme
  • European Federation of Pharmaceutical Industries and Associations
  • Innovative Medicines Initiative

Zitieren

APA

Chevet, B., Devauchelle-Pensec, V., Pontarini, E., Baloche, V., Bombardieri, M., Bowman, S. J., Barnes, M., Sreih, A. G., Liu, J., Kelly, S., Christodoulou, A., Moingeon, P., Laigle, L., Soret, P., Le Dantec, C., Pers, J. O., Alarcon-Riquelme, M. E., Barturen, G., Mariette, X., …, & PRECISEADS Clinical Consortium, NECESSITY consortium (2026). Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren’s disease. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.11.017

Vancouver

Chevet B, Devauchelle-Pensec V, Pontarini E, Baloche V, Bombardieri M, Bowman SJ, et al. Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren’s disease. Annals of the Rheumatic Diseases. 2026. doi:10.1016/j.ard.2025.11.017

BibTeX
@article{Chevet2026,
  author = {Chevet, Baptiste and Devauchelle-Pensec, Valérie and Pontarini, Elena and Baloche, Valentin and Bombardieri, Michele and Bowman, Simon J and Barnes, Michael and Sreih, Antoine G and Liu, Jinqi and Kelly, Sheila and Christodoulou, Antonia and Moingeon, Philippe and Laigle, Laurence and Soret, Perrine and Le Dantec, Christelle and Pers, Jacques-Olivier and Alarcon-Riquelme, Marta E and Barturen, Guillermo and Mariette, Xavier and van Roon, Joel and Seror, Raphaèle and Nocturne, Gaetane and Cornec, Divi and Foulquier, Nathan and PRECISEADS Clinical Consortium, NECESSITY consortium, PRECISEADS Clinical Consortium, NECESSITY consortium},
  title = {Transcriptomic stratification predicts response to rituximab, abatacept, or the association of hydroxychloroquine and leflunomide in 3 randomised controlled clinical trials of Sjögren’s disease},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  doi = {10.1016/j.ard.2025.11.017}
}
Kostenlos starten →